真实世界中美国医疗中心使用亚胺培南/西司他丁/雷巴他定的评估。
Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres.
机构信息
Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA.
Merck & Co., Inc., Rahway, NJ.
出版信息
J Glob Antimicrob Resist. 2024 Jun;37:190-194. doi: 10.1016/j.jgar.2024.03.002. Epub 2024 Apr 6.
PMID:38588973
Abstract
We assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, the median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support. The in-hospital mortality rate was 24%. These data advance our understanding of real-world indications and outcomes of imipenem/cilastatin/relebactam use.
摘要
我们评估了 160 例接受亚胺培南/西司他丁/雷巴他定治疗≥2 天的患者。在治疗开始时，Charlson 合并症指数中位数为 5，45%的患者在重症监护病房，19%的患者需要血管加压支持。院内死亡率为 24%。这些数据加深了我们对亚胺培南/西司他丁/雷巴他定实际应用指征和结果的理解。
Zotero 插件